V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Cogent Biosciences Executive Compensation (FY25)

COGT · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Andrew Robbins
Latest say-on-pay support
=
April 13, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Cogent Biosciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 11, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Cogent Biosciences brief$1,500Get the executive brief
Velarion Member, one year
277 figures on this page: 274 cited to the filing that reported them, 3 calculated from figures it prints. See the citations

More on Cogent Biosciences

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Andrew Robbins: $4,917,890 → $27,762,684

Frequently asked questions

Answers drawn from the data on this page.
Who is Cogent Biosciences' chief executive and what were they paid?
Andrew Robbins, Chief Executive Officer, President and Director, received $27,762,684 in total compensation for fiscal 2025. Compared with the $4,917,890 reported for fiscal 2024, Robbins' total was up.
What was Cogent Biosciences' say-on-pay result?
Shareholders recorded 90.2% support for the say-on-pay proposal at the meeting held April 13, 2026 for fiscal 2025.
Which companies are in Cogent Biosciences' peer group?
Companies named in the disclosed peer group include Allogene Therapeutics, Inc., AnaptysBio, Inc., Arcus Biosciences, Inc., Arvinas, Inc. and Bicycle Therapeutics plc, among others. The peer group established December 2025 includes Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc., BridgeBio Pharma, Inc., CG Oncology, Inc. and Corcept Therapeutics Incorporated, among others.
What is Cogent Biosciences' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 95:1, against median employee compensation of $292,285.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Robbins
Chief Executive Officer
◇◇—◇——◇◇
Jessica Sachs
Chief Medical Officer
◇◇—◇——◇◇
John Robinson
Chief Scientific Officer
◇◇—◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Robbins
Chief Executive Officer
◇◇◇◇——◇◇
Jessica Sachs
Chief Medical Officer
◇◇◇◇——◇◇
John Robinson
Chief Scientific Officer
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Robbins
Chief Executive Officer
◇——◇◇—◇◇
Cole Pinnow
Chief Commercial Officer
◇◇◇◇◇——◇
Jessica Sachs
Chief Medical Officer
◇——◇◇—◇◇
John Robinson
Chief Scientific Officer
◇——◇◇—◇◇
John Green
Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Robbins
Chief Executive Officer, President and Director
◇◇◇◇◇—◇◇
Jessica Sachs
Chief Medical Officer
◇◇◇◇◇—◇◇
John Robinson
Chief Scientific Officer
◇◇◇◇◇—◇◇
Cole Pinnow
Chief Commercial Officer
◇◇◇◇◇—◇◇
John Green
Chief Financial Officer
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew RobbinsOPTION◇——◇—◇◇
Andrew RobbinsPSU◇—◇—◇—◇
Andrew RobbinsRSU◇——◇——◇
Andrew RobbinsOPTION◇——◇—◇◇
Cole PinnowPSU◇—◇—◇—◇
Cole PinnowRSU◇——◇——◇
Cole PinnowOPTION◇——◇—◇◇
Cole PinnowOPTION◇——◇—◇◇
Jessica SachsRSU◇——◇——◇
Jessica SachsOPTION◇——◇—◇◇
Jessica SachsPSU◇—◇—◇—◇
Jessica SachsOPTION◇——◇—◇◇
John GreenOPTION◇——◇—◇◇
John GreenPSU◇—◇—◇—◇
John GreenRSU◇——◇——◇
John GreenOPTION◇——◇—◇◇
John RobinsonOPTION◇——◇—◇◇
John RobinsonRSU◇——◇——◇
John RobinsonPSU◇—◇—◇—◇
John RobinsonOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
John RobinsonOption◇—◇1/22/2034
Option◇—◇2/12/2033
Option◇—◇12/16/2035
RSU◇◇——
RSU◇◇——
Option◇—◇1/22/2035
Option◇—◇1/24/2032
Cole PinnowOption◇—◇12/16/2035
Option◇—◇05/24/2034
Option◇—◇01/22/2035
RSU◇◇——
RSU◇◇——
John GreenOption◇—◇1/22/2035
Option◇—◇1/24/2032
RSU◇◇——
Option◇—◇2/12/2033
RSU◇◇——
Option◇—◇1/22/2034
Option◇—◇12/16/2035
Andrew RobbinsOption◇—◇1/24/2032
RSU◇◇——
Option◇—◇12/16/2035
Option◇—◇1/22/2034
RSU◇◇——
Option◇—◇1/22/2035
Option◇—◇2/12/2033
Jessica SachsOption◇—◇1/22/2035
Option◇—◇2/12/2033
RSU◇◇——
Option◇—◇12/16/2035
RSU◇◇——
Option◇—◇1/22/2034
Option◇—◇1/24/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Peter Harwin
Board chair
◇—◇———◇
Todd Shegog
◇—◇———◇
Arlene M. Morris
◇—◇———◇
Chris Cain
◇—◇———◇
Karen Ferrante
◇—◇———◇
Matthew E. Ros
◇—◇———◇
Andrew Robbins served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Allogene Therapeutics, Inc. ALLO
  • AnaptysBio, Inc. ANAB
  • Arcus Biosciences, Inc. RCUS
  • Arvinas, Inc. ARVN
  • Bicycle Therapeutics plc BCYC
  • Blueprint Medicines Corporation BPMC
  • Celldex Therapeutics, Inc. CLDX
  • Day One Biopharmaceuticals, Inc. DAWN
  • Erasca, Inc. ERAS
  • IGM Biosciences, Inc. IGMS
  • Immunome, Inc. IMNM
  • Iovance Biotherapeutics, Inc. IOVA
  • Kiniksa Pharmaceuticals, Ltd. KNSA
  • Kura Oncology, Inc. KURA
  • Nuvalent, Inc. NUVL
  • Relay Therapeutics, Inc. RLAY
  • SpringWorks Therapeutics, Inc. SWTX
  • Syndax Pharmaceuticals, Inc. SNDX
  • Tyra Biosciences, Inc. TYRA
  • Xencor, Inc. XNCR
peer group established December 2025
  • Amicus Therapeutics, Inc. FOLD
  • Apellis Pharmaceuticals, Inc. APLS
  • BridgeBio Pharma, Inc. BBIO
  • CG Oncology, Inc. CGON
  • Corcept Therapeutics Incorporated CORT
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Cytokinetics, Incorporated CYTK
  • IDEAYA Biosciences, Inc. IDYA
  • Immunovant, Inc. IMVT
  • Mirum Pharmaceuticals, Inc. MIRM
  • Revolution Medicines, Inc. RVMD
  • TG Therapeutics, Inc. TGTX
  • Ultragenyx Pharmaceutical Inc. RARE

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 13, 2026=◇◇◇
2024June 4, 2025=◇◇◇
2023June 5, 2024=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Andrew Robbins (Chief Executive Officer, President and Director), FY2025 total compensation $27,762,684 (base salary $724,554) [exec_comp, SEC accession 0001193125-26-173834, filed 2026-04-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Cogent Biosciences files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Cogent Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Cogent Biosciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Cogent Biosciences' disclosed peer group is defensible, who names Cogent Biosciences back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
277 figures on this page: 274 cited to the filing that reported them, 3 calculated from figures it prints.
274 cited to the filing
3 calculated from the filing

Documents cited

  1. 0001193125-26-267566
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  2. 0001193125-26-173834
    2025 Summary Compensation Table · CEO PAY RATIO · Fiscal Year 2025 Director Compensation Table · Grants of Plan-Based Awards · and 2 more sections
  3. 0001193125-25-135337
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  4. 0001193125-25-089237
    Summary Compensation Table
  5. 0001193125-24-155116
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-24-107124
    Summary Compensation Table
  7. 0001193125-23-115281
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Cogent Biosciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/COGT (accessed 2026).
Short form: data: Velarion

The paid brief for Cogent Biosciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Cogent Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Cogent Biosciences discloses

The companies named in COGT's own disclosed peer group.

Allogene Therapeutics, Inc.AnaptysBio, Inc.Arcus Biosciences, Inc.Arvinas, Inc.Bicycle Therapeutics plcBlueprint Medicines CorporationCelldex Therapeutics, Inc.Day One Biopharmaceuticals, Inc.Erasca, Inc.IGM Biosciences, Inc.Immunome, Inc.Iovance Biotherapeutics, Inc.Kiniksa Pharmaceuticals, Ltd.Kura Oncology, Inc.Nuvalent, Inc.Relay Therapeutics, Inc.SpringWorks Therapeutics, Inc.Syndax Pharmaceuticals, Inc.Tyra Biosciences, Inc.Xencor, Inc.Amicus Therapeutics, Inc.Apellis Pharmaceuticals, Inc.BridgeBio Pharma, Inc.CG Oncology, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy